Pharma Focus Asia

Eli Lilly to Invest US$470million for Pharmaceutical Plant Construction

Introduction:

Eli Lilly and Company will invest US$470 million for the construction of a new state-of-the-art pharmaceutical manufacturing facility in North Carolina's Research Triangle Park.

Features:

The new manufacturing site will manufacture parenteral/injectable products and delivery devices.

The new facility will allow Eli Lilly to expand its capacity to make the company's medicines that are helping people will serious illnesses and help the company prepare for new medicines coming from its robust pipeline in the future.

The North Carolina General Assembly, the North Carolina Community College System, the North Carolina Biotechnology Center, Durham County, the Greater Durham Chamber of Commerce and Duke Energy have partnered with N.C. Commerce and the Economic Development Partnership of N.C. on this project.

Specifications:

NameEli Lilly and Company 
TypeConstruction
BudgetUS$470million
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference